FDA Botanical Drug Pathway for Cannabis: Why Zero Approvals Exist
The FDA botanical drug pathway cannabis presents unique challenges that have prevented approvals of cannabis-derived products. Scientific, regulatory, and logistical barriers contribute to this gap. Understanding these obstacles is essential for…
Canada 2015 Cannabis Survey: Medical vs Recreational User Profiles
The cannabis epidemiology medical cannabis population survey from 2015 reveals key differences between medical and recreational users in Canada before legalization. Medical users tended to be older, in poorer health, and used cannabis more frequently.…
Selonabant Blocks THC High in Phase II Trial | Evidence Watch
The selonabant CB1 antagonist sharply reduced subjective THC intoxication in a sponsored Phase II trial of healthy volunteers. Because selonabant was given alongside THC rather than after intoxication set in, the study cannot confirm whether it would…
Multi-Modal Cannabis Use Among Young Adults: BRFSS 2022-2023
Multi-modal cannabis use young adults is increasingly common, with over half using multiple consumption methods. The 2022-2023 BRFSS survey reveals key patterns and risk factors. Understanding these trends is vital for clinical screening and public…
Medical Cannabis and Healthcare Professionals: Beyond Knowledge Gaps
Medical cannabis implementation faces challenges beyond knowledge gaps among healthcare professionals. This review highlights the importance of social norms, professional identity, and environmental barriers. Addressing these factors is crucial for…
Blowing Minds Cannabis Study Protocol: What It Plans to Discover
The cannabis use mental health study protocol outlines a two-year multinational research design to assess cannabis effects on mood, cognition, and mental health. This longitudinal study uses real-time mobile sampling to reduce recall bias and compares…
Cannabis and Cancer Pain: Evidence Gaps in Opioid Substitution
Cannabis opioid substitution cancer pain is a growing area of clinical interest as new data show reduced opioid use but increased adverse hospital events. This evidence gap challenges clinicians and policymakers to balance benefits and risks. More…
Challenges in Cannabinoid HIV Clinical Trials: Enrollment and Stigma
Cannabinoid HIV clinical trials face significant enrollment challenges despite legal cannabis access. A Montreal pilot trial enrolled only 10 of 26 planned participants due to stigma and visit burden. This study highlights critical barriers future…
Cannabis Legalization and Pediatric Poisonings: A Global Health Perspective
Cannabis legalization pediatric poisonings have risen in multiple regions, highlighting a critical public health concern. This review surveys global evidence on pediatric emergency visits and safety challenges. Understanding these risks is essential for…
Cannabis and Autism: What 5,900 Tracking Sessions Really Show
The cannabis autism symptom tracking study analyzed nearly 6,000 sessions from self-identified autistic adults. Participants reported significant symptom relief after inhaled cannabis use. However, the study's design limits conclusions about cannabis…